bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
pharma · Systemic Amyloidosis
Jin Lu, MD
Jin Lu, MD drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Jin Lu, MD pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Jin Lu, MD drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.